CCRM
Megha Shah is a Quality Control Associate at CCRM since May 2022, with prior experience as a Biotech Analyst and Biotech Laboratory Technician at SGS from November 2019 to May 2022, where responsibilities included conducting routine QC testing and validating methods for drug substances. Megha has also worked as a Medical Laboratory Technician at IDEXX, demonstrating skills in ELISAs and specimen processing, and held various roles such as Sales Associate at GNC and a Security Guard at Tone-Gar Security Services Inc. Previous internship experience includes a Microbiology Intern position at SGS and a Molecular Biology Intern role at Sardar Patel University, focusing on the relationship between SNPs and diabetes onset. Megha holds an Advanced Diploma in Biotechnology - Forensics from Fleming College and a Master's degree in Integrated Medical Biotechnology from Sardar Patel University.
CCRM
1 followers
Regenerative Medicine (RM), which aims to harness the power of stem cells, biomaterials and molecules to repair, regenerate or replace diseased cells, tissues and organs, has the promise to treat, manage and perhaps cure some of the most devastating and costly diseases in the world today. Many new and potentially life-changing RM-based treatments never reach patients because they are not successfully moved from the laboratory to a stage where they can be used in medicine. In order to fulfill RM’s promise to treat the many diseases affecting our population, a world-renowned group of stem cell scientists and engineers have come together to form CCRM, a leader in developing and commercializing regenerative medicine and cell therapy technologies. CCRM formally launched on June 14, 2011. CCRM supports the development and commercialization of regenerative medicines and associated enabling technologies, with a specific focus on cell and gene therapy.